Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2020 01:00 ET | Source: Angion Biomedica Corp

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is a first-in-class small-molecule hepatocyte growth factor (HGF) mimetic,...
October 09, 2020 10:33 ET | Source: Angion Biomedica Corp

Angion to Present Multiple Posters at Kidney Week 2020

SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
August 04, 2020 00:01 ET | Source: Angion Biomedica Corp

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

SAN FRANCISCO and COVINGTON, Ky., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and...
July 08, 2020 00:01 ET | Source: Angion Biomedica Corp

Angion Initiates Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

SAN FRANCISCO, July 08, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
June 04, 2020 00:01 ET | Source: Angion Biomedica Corp

Angion Announces Key Addition to Management Team and Appointments to Board of Directors

Appoints Jennifer J. Rhodes as Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary - - - Strengthens the Board of Directors with the addition of industry...
May 29, 2020 10:22 ET | Source: Angion Biomedica Corp

Angion to Present Results from Multiple Preclinical and Health Economic Studies at the American Transplant Congress Virtual Meeting

SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small...
May 05, 2020 00:01 ET | Source: Angion Biomedica Corp

Angion Announces Publication of ANG-3777 Phase 2 Results in the Scientific Journal Transplantation

SAN FRANCISCO, May 05, 2020 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
December 18, 2019 10:00 ET | Source: Angion Biomedica Corp

Angion Initiates Dosing in Phase 1 Clinical Trial Evaluating ANG-3070, a Dual-Kinase Inhibitor for the Treatment of Fibrotic Diseases

SAN FRANCISCO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing first-in-class therapies to treat acute kidney injury and...
November 11, 2019 10:00 ET | Source: Angion Biomedica Corp

Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019

SAN FRANCISCO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion), a clinical stage biopharmaceutical company developing a first-in-class therapy to treat acute kidney injury,...
November 07, 2019 12:15 ET | Source: Angion Biomedica Corp

Angion Presents Positive Long-term Data from Phase 2 Clinical Trial of ANG-3777 in Delayed Graft Function at the American Society of Nephrology Kidney Week 2019

ANG-3777 shows improved short- and long-term graft function with a positive safety profile in a Phase 2 study New data support company’s ongoing Phase 3 study UNIONDALE, N.Y., Nov. 07, 2019 ...